BioinvestGPT

BioinvestGPT ApS · Research use only

NCT06333860 (Risankizumab in Moderate Plaque Psoriasis): BVCT ex-ante prediction vs. reported outcome

On 24 Feb 2025, BioinvestGPT's BVCT predicted technical success and commercial success for this trial. The 10 Nov 2025 readout is classified on the dashboard as True Positive (TP), a correct prediction. Recorded clinical-benefit conclusion: statistically significant and commercially sufficient.

Clinical Trial

NCTID
NCT06333860
Acronym
IMMpactful
Drug Name
Risankizumab
Drug MoA
IGG1 anti-IL23p19 inhibitor
Drug Modality
monoclonal antibody
Drug Class
Best-In-Class
Therapeutic Area
Immune System Diseases
Indication
Moderate Plaque Psoriasis
Human Patients
393
Sponsor
AbbVie
Phase
Phase 4

Prediction of , index 1939

Prospective Prediction
Prediction Index
1939
Prediction Date
Commercial Prediction
SUCCESS (commercially sufficient clinical benefit in sPGA0/PASI90 slightly superior to icotrokinra and non-inferior to bimekizumab)
Technical Prediction
SUCCESS (statistically significant clinical benefit in sPGA0/PASI90 superior to deucravacitinib)

Readout of

Prediction Validation
Readout Date
Prediction To Readout
259 days in advance
Readout Data Interpretation
Risankizumab achieved 34.4% deucravacitinib-controlled PASI90 improvement at week 16 (57.3% vs 22.9% P < 0.0001) and 40.5% deucravacitinib-controlled sPAG 0/1 improvement at week 16 (80.2% vs 39.7% P < 0.0001), which is superior to 23-25% deucravacitinib-controlled PASI90 improvement and 16-18% deucravacitinib-controlled sPAG0/1 improvement at week 16 achieved by icotrokinra (see add'l link below)
Press Release
Additional Readout Data
Prediction Result
Prediction Accuracy
Correct Prediction
Clinical Benefit Conclusion
statistically significant and commercially sufficient
Prediction Classification
True Positive (TP)

ClinicalTrials.gov record

ClinicalTrials.gov record, retrieved 2026-09-24. Third-party data.

Official title
A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor Blinded Study of Risankizumab Compared to Deucravacitinib for the Treatment of Adult Subjects With Moderate Plaque Psoriasis Who Are Candidates for Systemic Therapy
Phase
Phase 4
Status
Completed
Enrollment
393
Lead sponsor
AbbVie
Conditions
Moderate Plaque Psoriasis
Interventions
DRUG: Risankizumab; DRUG: Deucravacitinib
Design
Randomized · Parallel · Single
Primary purpose
Treatment
Start
2024-05-10
Primary completion
2026-03-19
Completion
2026-03-19
Primary outcomes
  • Period A: Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90) (At Week 16)
  • Period A: Percentage of Participants Achieving a Static Physician Global Assessment (sPGA) Score of 0 (Clear) or 1 (Almost Clear) with at least 2-grade improvement from Baseline (Baseline, Week 16)
  • Period B: Percentage of Participants Achieving 90% Improvement in Psoriasis Area Severity Index (PASI) Score (PASI 90) in the Intent to Treat Population for non-responders in Period B (ITT_B_NR). (At Week 52)
  • Number of Participants Experiencing Adverse Events (AEs) (Baseline up to 73 Weeks)

NCT06333860 on ClinicalTrials.gov

Return to the dashboardClinicalTrials.gov

How to read these records: evidence · methodology · all trials